Formulation development & stability of the 166Ho-DOTMP for high level dosages -: A skeletal targeted radiotherapeutic.

被引：0
作者：
John, EK [1 ]
Boone, J [1 ]
Hsiao, P [1 ]
Aberion, D [1 ]
Resol, E [1 ]
Bottino, B [1 ]
机构：
[1] NEORX Corp, Seattle, WA 98119 USA
来源：
JOURNAL OF NUCLEAR MEDICINE | 2001年 / 42卷 / 05期
关键词：
D O I：
暂无
中图分类号：
R8 [特种医学]; R445 [影像诊断学];
学科分类号：
1002 ; 100207 ; 1009 ;
摘要：
1122
引用
收藏
页码：267P / 267P
页数：1
相关论文
共 14 条
  • [1] Dosimetry of high dose skeletal targeted radiotherapy (STR) with 166Ho-DOTMP
    Breitz, H
    Wendt, R
    Stabin, M
    Bouchet, L
    Wessels, B
    CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS, 2003, 18 (02) : 225 - 230
  • [2] Skeletal localization and renal elimination of the skeletal targeted radiotherapeutic (STR), 166Ho-DOTMP.
    Schneidkraut, MJ
    Jones, HM
    Hargreaves, KA
    FASEB JOURNAL, 2004, 18 (04) : A606 - A606
  • [3] 166Ho-DOTMP radiation-absorbed dose estimation for skeletal targeted radiotherapy
    Breitz, Hazel B.
    Wendt, Richard E.
    Stabin, Michael S.
    Shen, Sui
    Erwin, William D.
    Rajendran, Joseph G.
    Eary, Janet F.
    Durack, Lawrence
    Delpassand, Ebrahim
    Martin, William
    Meredith, Ruby F.
    JOURNAL OF NUCLEAR MEDICINE, 2006, 47 (03) : 534 - 542
  • [4] 166Ho-DOTMP Skeletal Targeted Radiotherapy with melphalan and autologous stem cell support for multiple myeloma
    Bensinger, W
    Giralt, S
    Goodman, M
    Salzman, D
    Ruffner, K
    Breitz, H
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 596S - 596S
  • [5] 166Ho-DOTMP Skeletal Targeted Radiotherapy™ as conditioning for peripheral blood stem cell transplant for patients with multiple myeloma
    Breitz, H
    Wendt, R
    Stabin, M
    Shen, S
    Rajendran, JG
    Meredith, R
    Martin, W
    Serafini, A
    Delpassand, E
    Bensinger, W
    Salzman, D
    Ruffner, K
    Goodman, M
    Giralt, S
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2004, 31 : S291 - S292
  • [6] Long-term safety and efficacy data supporting new dosing of 166Ho-DOTMP skeletal targeted radiotherapy for multiple myeloma
    Giralt, S
    Bensinger, W
    Goodman, M
    Gray, D
    Sims, R
    Breitz, H
    BLOOD, 2003, 102 (11) : 985A - 985A
  • [7] High-dose 166Ho-DOTMP in myeloablative treatment of multiple myeloma:: Pharmacokinetics, biodistribution, and absorbed dose estimation
    Rajendran, JG
    Eary, JF
    Bensinger, W
    Durack, LD
    Vernon, C
    Fritzberg, A
    JOURNAL OF NUCLEAR MEDICINE, 2002, 43 (10) : 1383 - 1390
  • [8] Targeted radiotherapy to the skeleton using 166HO-DOTMP with autologous stem cell transplantation for patients with bone-only metastatic breast cancer
    Champlin, RE
    Booser, D
    Rondon, G
    Williams, PA
    Wendt, R
    Hortobagyi, G
    Ueno, N
    Podoloff, D
    BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2005, 11 (02) : 84 - 85
  • [9] Targeted radiotherapy to the skeleton using 166Ho-DOTMP with autologous stem cell transplantation for patients with bone-only metastatic breast cancer
    Champlin, R
    Booser, D
    Rondon, G
    Williams, P
    Wendt, R
    Hortobagyi, G
    Ueno, N
    Podoloff, D
    BLOOD, 2004, 104 (11) : 395B - 395B
  • [10] Reduced administration rate of 166Ho-DOTMP attenuates peak blood and renal radiation exposure without compromising skeletal localization in rats.
    Ness, D
    Hicks, J
    Jones, HM
    Auditore-Hargreaves, K
    Schneidkraut, MJ
    BLOOD, 2002, 100 (11) : 391B - 392B
12